Software-as-Treatment Startup Click Therapeutics Gets FDA Authorization for Migraine Mobile App

**FDA Authorizes Click Therapeutics’ Mobile App for Migraine Prevention**

The U.S. Food and Drug Administration (FDA) has authorized a mobile application developed by Click Therapeutics for use in preventing episodic migraines in adults. The app, designed to complement standard drug therapies, demonstrated a statistically significant reduction in monthly migraine days during clinical trials when used daily.

Click Therapeutics’ digital tool represents an emerging category of software-based treatments aimed at managing chronic conditions. The company conducted clinical trials to evaluate the app’s effectiveness, with results showing measurable improvements in reducing the frequency of migraines among users. This FDA authorization allows the app to be prescribed alongside traditional medication as part of a comprehensive approach to migraine prevention.

Newsflash | Powered by GeneOnline AI

Source: https://medcitynews.com/2025/04/software-as-treatment-startup-click-therapeutics-gets-fda-authorization-for-migraine-mobile-app/

Author

Mark Chiang